Abstract
Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 29-38 |
| Number of pages | 10 |
| Journal | Sarcoidosis Vasculitis and Diffuse Lung Diseases |
| Volume | 33 |
| Issue number | 1 |
| State | Published - Jan 1 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- Fibrosis
- Metabolomics
- Sarcoidosis
ASJC Scopus subject areas
- Internal Medicine
- Immunology and Allergy
- Pulmonary and Respiratory Medicine
Cite this
Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. / Mirsaeidi, Mehdi; Banoei, Mohammad Mehdi; Nienow, Caleb K.; Abassi, Taimur; Hakim, Anoushirvan; Schraufnagel, Dean; Winston, Brent W.; Sweiss, Nadera; Baughman, Robert; Garcia, Joe G.N.; Machado, Roberto.
In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 33, No. 1, 01.01.2016, p. 29-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Plasma metabolomic profile in fibrosing pulmonary sarcoidosis
AU - Mirsaeidi, Mehdi
AU - Banoei, Mohammad Mehdi
AU - Nienow, Caleb K.
AU - Abassi, Taimur
AU - Hakim, Anoushirvan
AU - Schraufnagel, Dean
AU - Winston, Brent W.
AU - Sweiss, Nadera
AU - Baughman, Robert
AU - Garcia, Joe G.N.
AU - Machado, Roberto
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).
AB - Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).
KW - Fibrosis
KW - Metabolomics
KW - Sarcoidosis
UR - http://www.scopus.com/inward/record.url?scp=84963964179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963964179&partnerID=8YFLogxK
M3 - Article
C2 - 27055833
AN - SCOPUS:84963964179
VL - 33
SP - 29
EP - 38
JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases
JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases
SN - 1124-0490
IS - 1
ER -